Quercetin suppresses lung cancer growth by targeting Aurora B kinase

Quercetin suppresses NLRP3 inflammasome activation and attenuates histopathology in a rat model of spinal cord injury

(2016) W Jiang et al.   SPINAL CORD

Quercetin Enhances Chemosensitivity to Gemcitabine in Lung Cancer Cells by Inhibiting Heat Shock Protein 70 Expression

(2015) Seung Hyeun Lee et al.   Clinical Lung Cancer

Aurora B Overexpression Causes Aneuploidy and p21Cip1Repression during Tumor Development

(2015) Alejandra González-Loyola et al.   MOLECULAR AND CELLULAR BIOLOGY

Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview

(2014) Dorina Gheorgheosu et al.   Anti-Cancer Agents in Medicinal Chemistry

Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

(2014) Chun Hei Antonio Cheung et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors

(2014) Christian Dittrich et al.   INVESTIGATIONAL NEW DRUGS

3,6,2′,4′,5′-Pentahydroxyflavone, an Orally Bioavailable Multiple Protein Kinase Inhibitor, Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer

(2014) Yuqiao Sheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Curcumin and quercetin trigger apoptosis during benzo(a)pyrene-induced lung carcinogenesis

(2014) Praveen Nair et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The role of Aurora B expression in non-tumor liver tissues of patients with hepatocellular carcinoma

(2013) Lkhagva-Ochir Tovuu et al.   International Journal of Clinical Oncology

Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer

(2013) Masafumi Takeshita et al.   LUNG CANCER

Identification of an Aurora Kinase Inhibitor Specific for the Aurora B Isoform

(2012) H. Xie et al.   CANCER RESEARCH

Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B

(2012) Xiang Li et al.   CARCINOGENESIS

Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer

(2011) G. Portella et al.   CURRENT MEDICINAL CHEMISTRY

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

(2011) Ron J. Keizer et al.   INVESTIGATIONAL NEW DRUGS

The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas

(2010) Christian Senft et al.   BMC CANCER

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Protein-binding assays in biological liquids using microscale thermophoresis

(2010) Christoph J. Wienken et al.   Nature Communications

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models

(2009) M. A. Hardwicke et al.   MOLECULAR CANCER THERAPEUTICS

Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells

(2008) A. M. D'Alise et al.   MOLECULAR CANCER THERAPEUTICS